Literature DB >> 9817404

Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial.

M B Bracken1, M J Shepard, T R Holford, L Leo-Summers, E F Aldrich, M Fazl, M G Fehlings, D L Herr, P W Hitchon, L F Marshall, R P Nockels, V Pascale, P L Perot, J Piepmeier, V K Sonntag, F Wagner, J E Wilberger, H R Winn, W Young.   

Abstract

OBJECT: A randomized double-blind clinical trial was conducted to compare neurological and functional recovery and morbidity and mortality rates 1 year after acute spinal cord injury in patients who had received a standard 24-hour methylprednisolone regimen (24MP) with those in whom an identical MP regimen had been delivered for 48 hours (48MP) or those who had received a 48-hour tirilazad mesylate (48TM) regimen.
METHODS: Patients for whom treatment was initiated within 3 hours of injury showed equal neurological and functional recovery in all three treatment groups. Patients for whom treatment was delayed more than 3 hours experienced diminished motor function recovery in the 24MP group, but those in the 48MP group showed greater 1-year motor recovery (recovery scores of 13.7 and 19, respectively, p=0.053). A greater percentage of patients improving three or more neurological grades was also observed in the 48MP group (p=0.073). In general, patients treated with 48TM recovered equally when compared with those who received 24MP treatments. A corresponding recovery in self care and sphincter control was seen but was not statistically significant. Mortality and morbidity rates at 1 year were similar in all groups.
CONCLUSIONS: For patients in whom MP therapy is initiated within 3 hours of injury, 24-hour maintenance is appropriate. Patients starting therapy 3 to 8 hours after injury should be maintained on the regimen for 48 hours unless there are complicating medical factors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9817404     DOI: 10.3171/jns.1998.89.5.0699

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  70 in total

1.  Methylprednisolone for acute spinal cord injury: not a standard of care.

Authors:  Herman Hugenholtz
Journal:  CMAJ       Date:  2003-04-29       Impact factor: 8.262

Review 2.  Biomaterial Approaches to Modulate Reactive Astroglial Response.

Authors:  Jonathan M Zuidema; Ryan J Gilbert; Manoj K Gottipati
Journal:  Cells Tissues Organs       Date:  2018-12-05       Impact factor: 2.481

Review 3.  A systematic review of the effects of pharmacological agents on walking function in people with spinal cord injury.

Authors:  Antoinette Domingo; Abdulaziz A Al-Yahya; Yousif Asiri; Janice J Eng; Tania Lam
Journal:  J Neurotrauma       Date:  2012-02-29       Impact factor: 5.269

4.  The effect of minocycline on motor neuron recovery and neuropathic pain in a rat model of spinal cord injury.

Authors:  Dong Charn Cho; Jin Hwan Cheong; Moon Sul Yang; Se Jin Hwang; Jae Min Kim; Choong Hyun Kim
Journal:  J Korean Neurosurg Soc       Date:  2011-02-28

Review 5.  Bone marrow stem cells and polymer hydrogels--two strategies for spinal cord injury repair.

Authors:  Eva Syková; Pavla Jendelová; Lucia Urdzíková; Petr Lesný; Ales Hejcl
Journal:  Cell Mol Neurobiol       Date:  2006-04-22       Impact factor: 5.046

Review 6.  Neuro-ophthalmic deficits after head trauma.

Authors:  Sarah M Jacobs; Gregory P Van Stavern
Journal:  Curr Neurol Neurosci Rep       Date:  2013-11       Impact factor: 5.081

Review 7.  Antioxidant therapies for acute spinal cord injury.

Authors:  Edward D Hall
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

Review 8.  Molecular targets in spinal cord injury.

Authors:  Stefan Klussmann; Ana Martin-Villalba
Journal:  J Mol Med (Berl)       Date:  2005-08-02       Impact factor: 4.599

9.  VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.

Authors:  Erica K M Reeves; Eric P Hoffman; Kanneboyina Nagaraju; Jesse M Damsker; John M McCall
Journal:  Bioorg Med Chem       Date:  2013-02-18       Impact factor: 3.641

10.  Serum leptin levels following acute experimental spinal cord injury.

Authors:  Ali Riza Gezici; Ruchan Ergun; Alper Karakas; Bulent Gunduz
Journal:  J Spinal Cord Med       Date:  2009       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.